Business
Director/PDMR Shareholding
Director/PDMR Shareholding.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n\nPoolbeg Pharma plc \n \nDirector Dealing\n25 June 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, confirms that as announced on 20 May 2025, Mr Cathal Friel, Executive Chair and PDMR of the Company, participated in the Fundraising subscribing for 4,000,000 new Ordinary Shares at a price of 2.5p per share (the Issue Price). Following the AGM earlier this week, the New Ordinary Shares issued pursuant to the Fundraising were admitted to trading at 8am today.\n \nFollowing this transaction, Cathal Friel holds a total of 41,219,757 ordinary shares in the Company, representing approximately 5.91% of the Company's issued share capital.\n \n \nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:\n \n\n\n\n\n1\n\n\nDetails of the person discharging managerial responsibilities/person closely associated\n\n\n\n\na.\n\n\nName of PDMR\n\n\nCathal Friel\n\n\n\n\n2\n\n\nReason for notification\n \n\n\n\n\na.\n\n\nPosition/Status\n\n\nExecutive Chair\n\n\n\n\nb.\n\n\nInitial notification/\nAmendment\n\n\nInitial notification\n\n\n\n\n3\n\n\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\n\n\n\n\na.\n\n\nName\n\n\nPoolbeg Pharma plc\n\n\n\n\nb.\n\n\nLEI\n\n\n213800UZ8WJLWYHBFL52\n\n\n\n\n4\n\n\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n\n\n\n\na.\n\n\nDescription of the financial instrument, type of instrument\n\nIdentification Code\n\n\nOrdinary shares of 0.02 pence each\n \n \nISIN GB00BKPG7Z60\n\n\n\n\nb.\n\n\nNature of the transaction\n\n\nPurchase of ordinary shares in connection with the fundraising initially announced on 20 May 2025.\n\n\n\n\nc.\n\n\nPrice(s) and volume(s)\n\n\nPrice(s)\n\n\nVolume(s)\n\n\n\n\n2.5p\n\n\n4,000,000\n\n\n\n\nd.\n\n\nAggregated information\n \n- Aggregated Volume\n \n- Price\n\n\n \nAs in 4c) above\n \n \n\n\n\n\ne.\n\n\nDate of the transaction\n\n\n25 ...